Retinitis Pigmentosa (Retinitis) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

  • ID: 4038558
  • Drug Pipelines
  • Region: Global
  • 100 pages
  • DelveInsight
1 of 3
This report, “Retinitis Pigmentosa (Retinitis) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Retinitis Pigmentosa (Retinitis) Report is to understand the market and pipeline status of the drugs around the Retinitis Pigmentosa (Retinitis) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The This report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Retinitis Pigmentosa (Retinitis). While the leading brands, companies and chemicals are considered thoroughly, This report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please Note: This report requires certain updates. We have all the information available but require 48 Hours to complete the process and ensure it is as up - to - date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope::
  • A snapshot of the global Market and Phase III therapeutics scenario for Retinitis Pigmentosa (Retinitis).
  • A review of the marketed products under prescription for Retinitis Pigmentosa (Retinitis), regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges.
  • Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
  • Product profiles for marketed products for Retinitis Pigmentosa (Retinitis) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
  • Coverage of API Manufacturers for Retinitis Pigmentosa (Retinitis) drugs in the United States, Europe and Asian Regions with location details.
  • Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Retinitis Pigmentosa (Retinitis) drugs.
  • Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Retinitis Pigmentosa (Retinitis) drugs.
  • Coverage of Retinitis Pigmentosa (Retinitis) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
  • Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
  • Key discontinued Marketed products.
  • Global Sales Figure to 2018.
Reasons to Buy:
  • Evaluate the marketing status and exclusivity details of Retinitis Pigmentosa (Retinitis) key products to exploit opportunities for generic drug development opportunities.
  • Identify and understand important and diverse types of therapeutics under Phase III development for Retinitis Pigmentosa (Retinitis).
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Retinitis Pigmentosa (Retinitis).
  • API intelligence over marketed drugs forRetinitis Pigmentosa (Retinitis)and gaining primary intelligence over active ingredients manufacturers across the globe.
  • API intelligence over leading Phase III Pipeline drugs.
  • Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
  • Understanding the
  • Scope of the Phase III Drugs with nil regulatory filings.
  • Understanding the chemical route of synthesis of approved drugs for Retinitis Pigmentosa (Retinitis).
  • Uncovering opportunities in the rapidly growing US market.
Delivery Time: 2 Working Days.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Indication Overview

2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline

3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography

4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Retinitis Pigmentosa (Retinitis)
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials

7. Phase III Drugs for Retinitis Pigmentosa (Retinitis)
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)

8. Discontinued Drugs for Retinitis Pigmentosa (Retinitis)

9. Appendix

10. Methodology

11. Consulting Services

12. Contact Us

13. Disclaimer

List of Tables
Retinitis Pigmentosa (Retinitis) Therapeutic Market, US, Marketed Drugs by Application Type, 2017
Retinitis Pigmentosa (Retinitis) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
Retinitis Pigmentosa (Retinitis) Therapeutic Market, US, (Year), 2017
Retinitis Pigmentosa (Retinitis) Marketed Drugs, API Manufacturers by US DMF Status, 2017
Retinitis Pigmentosa (Retinitis) Marketed Drugs, US DMF Status Drug Specific (Number), 2017
Retinitis Pigmentosa (Retinitis) Drugs, API Manufacturers, Europe by Country, 2017
Retinitis Pigmentosa (Retinitis) Drugs, API Manufacturers, India by State, 2017
Retinitis Pigmentosa (Retinitis) Drugs, API Manufacturers, China by Province, 2017
Retinitis Pigmentosa (Retinitis) Drugs, API Manufacturers by Geography 2017
Retinitis Pigmentosa (Retinitis) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
Retinitis Pigmentosa (Retinitis) Therapeutic Market, Global Sales-2018 (in million USD)
API Manufacturers for Drug, 2017
Phase III Drugs for Retinitis Pigmentosa (Retinitis), 2017
Discontinued Drugs for Retinitis Pigmentosa (Retinitis), 2017

List of Figures
Retinitis Pigmentosa (Retinitis) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
Retinitis Pigmentosa (Retinitis) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
Retinitis Pigmentosa (Retinitis) Therapeutic Market, US, (Year), 2017
Retinitis Pigmentosa (Retinitis) Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
Retinitis Pigmentosa (Retinitis) Marketed Drugs, US DMF Status Drug Specific (Number), 2017
Retinitis Pigmentosa (Retinitis) Drugs, API Manufacturers, Europe by Country, 2017
Retinitis Pigmentosa (Retinitis) Drugs, API Manufacturers, India by State, 2017
Retinitis Pigmentosa (Retinitis) Drugs, API Manufacturers, China by Province, 2017
Retinitis Pigmentosa (Retinitis) Drugs, API Manufacturers by Geography 2017
Retinitis Pigmentosa (Retinitis) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
Retinitis Pigmentosa (Retinitis) Therapeutic Market, Global Sales 2018 (in million USD)
Drug, Patent/Exclusivity Expiry (Year), 2017
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll